Business Context and Reporting Period
Company: Revelation Biosciences, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 11, 2025
Event Date: September 10, 2025
Context: The Company entered into a warrant exercise inducement agreement to raise capital for clinical development and working capital.
Key Financial Metrics
- Gross Proceeds: Approximately $9.6 million from the exercise of 13,065,000 Existing Warrants.
- Exercise Price: $2.20 per share.
- Shares Issued: 4,355,000 shares of common stock upon exercise of Existing Warrants.
- Transaction Fees: 8% of aggregate gross proceeds paid to Roth Capital Partners, LLC as a financial advisory fee.
- Net Proceeds: Not explicitly stated; gross proceeds are before deducting financial advisory fees.
- Debt and Liquidity: The filing does not provide specific debt balances or total liquidity figures; proceeds are intended to fund working capital.
Material Changes
The primary material change is the conversion of 13,065,000 Class H Common Stock Warrants into 4,355,000 shares of common stock. In exchange, the Company issued 13,065,000 new Class I Common Stock Warrants to the exercising holders. This transaction increases the Company's cash position by approximately $9.6 million (gross) and alters the capital structure through the issuance of new equity and warrants.
Guidance, Outlook, and Risks
- Use of Proceeds: Net proceeds will be used for clinical development plans, working capital, and general corporate purposes.
- New Warrant Terms: Class I Warrants have an exercise price of $2.20 per share, are exercisable for five years from the date of stockholder approval, and are not exercisable until such approval is obtained.
- Regulatory Requirements: The Company must file a resale registration statement on Form S-3 within twenty days of closing. The Class I Warrants were issued pursuant to Section 4(a)(2) and Rule 506(b) exemptions and are not currently registered.
- Risks: The transaction is contingent on stockholder approval for the new warrants to become exercisable. The filing notes that the securities may not be offered or sold in the U.S. except pursuant to an effective registration statement or applicable exemption.
Investor Verification Checklist
- Verify the exact amount of net proceeds after the 8% advisory fee deduction.
- Confirm the timeline for the filing of the Form S-3 resale registration statement (due within 20 days of closing).
- Monitor the status of stockholder approval required to make the new Class I Warrants exercisable.
- Review the impact of the 4,355,000 new shares on existing shareholder dilution.
- Check for any additional expenses reimbursed to the financial advisor beyond the 8% fee.